Please click on the ID to see detailed information about each entry.
The total number entries retrieved from this search areID | Sequence | Name | Nature of peptide or cargo | Assay | Tissue permeability | Tissue Sample | PUBMED ID |
---|---|---|---|---|---|---|---|
1245 | pGlu-HP | Thyrotropin-releasing hormone (TRH) | It is a tripeptide that used in the treatment of brain and spinal cord injury and certain CNS disorders, including Alzheimer’s disease and motor neuron disease (MND) | Radioimmunoassay and Liquid Scintillation Technique | Permeability coefficient (Kp)= 18.4*105 cm/h, Cumulative amount= 24.9± 1.7 µg/cm2, Enhancement factor (EF) =3.4 | Human epidermal membrane | 10205635 |
1246 | pGlu-HP | Thyrotropin-releasing hormone (TRH) | It is a tripeptide that used in the treatment of brain and spinal cord injury and certain CNS disorders, including Alzheimer’s disease and motor neuron disease (MND) | Radioimmunoassay and Liquid Scintillation Technique | Permeability coefficient (Kp)= 16.6*105 cm/h, Cumulative amount= 18.5± 2.1 µg/cm2, Enhancement factor (EF) =3.1 | Human epidermal membrane | 10205635 |
1247 | pGlu-HP | Thyrotropin-releasing hormone (TRH) | It is a tripeptide that used in the treatment of brain and spinal cord injury and certain CNS disorders, including Alzheimer’s disease and motor neuron disease (MND) | Radioimmunoassay and Liquid Scintillation Technique | Permeability coefficient (Kp)= 5.4*105 cm/h, Cumulative amount= 7.8± 1.7 µg/cm2, Enhancement factor (EF) =0 | Human epidermal membrane | 10205635 |
1248 | pGlu-3-methyl-HP | M-TRH | Analogue of TRH i.e. M-TRH is a potent analogue and stimulates the release of TSH from the pituitary seven to eight times that of the parental tripeptide. | Liquid Scintillation Technique | Permeability coefficient (Kp)= 32.0*105 cm/h, Cumulative amount= 41.5±4.9 µg/cm2, Enhancement factor (EF) =4.7 | Human epidermal membrane | 10205635 |
1249 | pGlu-3-methyl-HP | M-TRH | Analogue of TRH i.e. M-TRH is a potent analogue and stimulates the release of TSH from the pituitary seven to eight times that of the parental tripeptide. | Liquid Scintillation Technique | Permeability coefficient (Kp)=20.2*105 cm/h, Cumulative amount= 20.4± 3.6µg/cm2, Enhancement factor (EF) =3.0 | Human epidermal membrane | 10205635 |
1250 | pGlu-3-methyl-HP | M-TRH | Analogue of TRH i.e. M-TRH is a potent analogue and stimulates the release of TSH from the pituitary seven to eight times that of the parental tripeptide. | Liquid Scintillation Technique | Permeability coefficient (Kp)= 6.8*105 cm/h, Cumulative amount= 8.6± 1.0 µg/cm2, Enhancement factor (EF) =0 | Human epidermal membrane | 10205635 |
1251 | TPRL | Carboranyl pseudotetrapeptide analogue of the insect pyrokinin/PBAN neuropeptide family | Potent pheromonotropic/myotropic activity | Cockroach Myotropic Bioassay and Pheromonotropic Assay (Topical) | ~ 23 ng/female, ED50=25pmol, Maximal response=60pmol | After the scales were removed, 1µl of peptide solution was applied to the surface of the cuticle and smoothed evenly over the prepared surface | 8844762 |
1252 | TPRL | Carboranyl pseudotetrapeptide analogue of the insect pyrokinin/PBAN neuropeptide family | Potent pheromonotropic/myotropic activity | Cockroach Myotropic Bioassay and Pheromonotropic Assay (Topical) | ~ 62 ng/female, ED50=25pmol, Maximal response=60pmol | After the scales were removed, 1µl of peptide solution was applied to the surface of the cuticle and smoothed evenly over the prepared surface | 8844762 |
1253 | TPRL | Carboranyl pseudotetrapeptide analogue of the insect pyrokinin/PBAN neuropeptide family | Potent pheromonotropic/myotropic activity | Cockroach Myotropic Bioassay and Pheromonotropic Assay (Topical) | ~ 70 ng/female, ED50=25pmol, Maximal response=60pmol | After the scales were removed, 1µl of peptide solution was applied to the surface of the cuticle and smoothed evenly over the prepared surface | 8844762 |
1254 | VTHRLAGLLSRSGGM VKSNFVPTNVGSKAF | CGRP receptor antagonist CGRP(8-37) | Regulation of blood flow, modulation of inflammation, and tissue remodelling | Photographed both hind paws using a micro-computer imaging device(MCID)-assessed analysis system. Immunostaining. Mann-Whitney U-test. | Effect of the CGRP-receptor antagonist CGRP(8-37)(~24.5 mm2) on the necrotic area in UV-damaged skin of the rat hindpaw compared to solvent applications(~36.5 mm2). | The dorsum of both hind paws were irradiated of male Sprague-Dawley (SD) rats. | 8584255 |
1255 | VTHRLAGLLSRSGGM VKSNFVPTNVGSKAF | CGRP receptor antagonist CGRP(8-37) | Regulation of blood flow, modulation of inflammation, and tissue remodelling | Photographed both hind paws using a micro-computer imaging device(MCID)-assessed analysis system. Immunostaining. Mann-Whitney U-test. | Effect of the CGRP-receptor antagonist CGRP(8-37)(~17 mm2) on the necrotic area in UV-damaged skin of the rat hindpaw compared to solvent applications(~25 mm2). | The dorsum of both hind paws were irradiated of male Sprague-Dawley (SD) rats. | 8584255 |
1256 | VTHRLAGLLSRSGGM VKSNFVPTNVGSKAF | CGRP receptor antagonist CGRP(8-37) | Regulation of blood flow, modulation of inflammation, and tissue remodelling | Photographed both hind paws using a micro-computer imaging device(MCID)-assessed analysis system. Immunostaining. Mann-Whitney U-test. | Effect of the CGRP-receptor antagonist CGRP(8-37)(~13 mm2) on the necrotic area in UV-damaged skin of the rat hindpaw compared to solvent applications(~16.5 mm2). | The dorsum of both hind paws were irradiated of male Sprague-Dawley (SD) rats. | 8584255 |
1257 | VTHRLAGLLSRSGGM VKSNFVPTNVGSKAF | CGRP receptor antagonist CGRP(8-37) | Regulation of blood flow, modulation of inflammation, and tissue remodelling | Photographed both hind paws using a micro-computer imaging device(MCID)-assessed analysis system. Immunostaining. Mann-Whitney U-test. | Effect of the CGRP-receptor antagonist CGRP(8-37)(~12 mm2) on the necrotic area in UV-damaged skin of the rat hindpaw compared to solvent applications(~14 mm2). | The dorsum of both hind paws were irradiated of male Sprague-Dawley (SD) rats. | 8584255 |
1258 | VTHRLAGLLSRSGGM VKSNFVPTNVGSKAF | CGRP receptor antagonist CGRP(8-37) | Regulation of blood flow, modulation of inflammation, and tissue remodelling | Photographed both hind paws using a micro-computer imaging device(MCID)-assessed analysis system. Immunostaining. Mann-Whitney U-test. | Effect of the CGRP-receptor antagonist CGRP(8-37)(~7 mm2) on the necrotic area in UV-damaged skin of the rat hindpaw compared to solvent applications(~13.5 mm2). | The dorsum of both hind paws were irradiated of male Sprague-Dawley (SD) rats. | 8584255 |
1262 | KRPPGFSPFR | Kallidin | Potent inflammatory mediators produced during acute and chronic inflammation.They are released at high nanomolar concentrations into the tear-film of ocular allergic patients. | Painful sensation assessed in a visual analogue scale(VAS) | Pain response obtained in nostrils after capsaicin pretreatment((50 nmol in 50 µl, everyday for 5-7 days): ~10.7(VAS value), the intensity of the sensation experienced with a single dose of capsaicin was considered the maximum value (i.e. 100) on the analogue scale, and all successive responses were scored in relation to this value. | Solution was applied by a micropipette into the nostril of thirty-four healthy volunteers of either sex | 8443036 |
1263 | KRPPGFSPFR | Kallidin | Potent inflammatory mediators produced during acute and chronic inflammation.They are released at high nanomolar concentrations into the tear-film of ocular allergic patients. | Painful sensation assessed in a visual analogue scale(VAS) | Pain response obtained in nostrils after capsaicin vehicle pretreatment: ~22(VAS value), the intensity of the sensation experienced with a single dose of capsaicin was considered the maximum value (i.e. 100) on the analogue scale, and all successive responses were scored in relation to this value. | Solution was applied by a micropipette into the nostril of thirty-four healthy volunteers of either sex | 8443036 |
1264 | KRPPGFSPFR | Kallidin | Potent inflammatory mediators produced during acute and chronic inflammation.They are released at high nanomolar concentrations into the tear-film of ocular allergic patients. | Painful sensation assessed in a visual analogue scale(VAS) | Pain response obtained in nostrils after capsaicin pretreatment((50 nmol in 50 µl, everyday for 5-7 days): ~20(VAS value), the intensity of the sensation experienced with a single dose of capsaicin was considered the maximum value (i.e. 100) on the analogue scale, and all successive responses were scored in relation to this value. | Solution was applied by a micropipette into the nostril of thirty-four healthy volunteers of either sex | 8443036 |
1295 | HDMNKVLDL | Nonapeptide P2 or AF-2 | Showed an anti-inflammatory effect in carrageenan-induced rat paw oedema, they inhibit pancreatic and Naja naja PLA2 in vitro and acute inflammatory processes induced by carrageenan or phorbol esters when administered locally or parenterally. | MPO and NAG assays | MPO levels(mU/ear)=Untreated(0.03)/Treated(1.72 ± 0.20), PGE2 levels(ng/ear)=Untreated(0)/Treated(83.2 ± 2.8), LTB4 levels(ng/ear)=Untreated(0)/Treated(15.2 ± 1.2) | Ear(auditory pinna) of male Swiss Webster mice | 7646536 |
1296 | HDMNKVLDL | Nonapeptide P2 or AF-2 | Showed an anti-inflammatory effect in carrageenan-induced rat paw oedema, they inhibit pancreatic and Naja naja PLA2 in vitro and acute inflammatory processes induced by carrageenan or phorbol esters when administered locally or parenterally. | MPO and NAG assays | MPO levels(mU/ear)=Untreated(0.03)/Treated(1.73 ± 0.13), PGE2 levels(ng/ear)=Untreated(0)/Treated(79.2 ± 3.1), LTB4 levels(ng/ear)=Untreated(0)/Treated(17.6 ± 1.3) | Ear(auditory pinna) of male Swiss Webster mice | 7646536 |
1297 | HDMNKVLDL | Nonapeptide P2 or AF-2 | Showed an anti-inflammatory effect in carrageenan-induced rat paw oedema, they inhibit pancreatic and Naja naja PLA2 in vitro and acute inflammatory processes induced by carrageenan or phorbol esters when administered locally or parenterally. | MPO and NAG assays | MPO levels(mU/ear)=Untreated(0.03)/Treated(1.68 ± 0.21), PGE2 levels(ng/ear)=Untreated(0)/Treated(80.1 ± 3.2), LTB4 levels(ng/ear)=Untreated(0)/Treated(18.1 ± 2.2) | Ear(auditory pinna) of male Swiss Webster mice | 7646536 |
1298 | HDMNKVLDL | Nonapeptide P2 or AF-2 | Showed an anti-inflammatory effect in carrageenan-induced rat paw oedema, they inhibit pancreatic and Naja naja PLA2 in vitro and acute inflammatory processes induced by carrageenan or phorbol esters when administered locally or parenterally. | MPO and NAG assays | MPO levels(mU/ear)=Untreated(0.02)/Treated(48.2 ± 3.2), NAG levels(mU/ear)=Untreated(23.1 ± 1.1)/Treated(39.1 ± 3.1), 6-keto-PGF1α(pg/ear)=Untreated(198 ± 22)/Treated(381 ± 31), LTB4 levels(pg/ear)=Untreated(0.30)/Treated(893 ± 161) | Ear(auditory pinna) of male Swiss Webster mice | 7646536 |
1299 | HDMNKVLDL | Nonapeptide P2 or AF-2 | Showed an anti-inflammatory effect in carrageenan-induced rat paw oedema, they inhibit pancreatic and Naja naja PLA2 in vitro and acute inflammatory processes induced by carrageenan or phorbol esters when administered locally or parenterally. | MPO and NAG assays | MPO levels(mU/ear)=Untreated(0.02)/Treated(42.7 ± 3.1), NAG levels(mU/ear)=Untreated(23.1 ± 1.1)/Treated(30.9 ± 2.9), 6-keto-PGF1α(pg/ear)=Untreated(198 ± 22)/Treated(Not defined), LTB4 levels(pg/ear)=Untreated(0.30)/Treated(697 ± 131) | Ear(auditory pinna) of male Swiss Webster mice | 7646536 |
1300 | HDMNKVLDL | Nonapeptide P2 or AF-2 | Showed an anti-inflammatory effect in carrageenan-induced rat paw oedema, they inhibit pancreatic and Naja naja PLA2 in vitro and acute inflammatory processes induced by carrageenan or phorbol esters when administered locally or parenterally. | MPO and NAG assays | MPO levels(mU/ear)=Untreated(0.02)/Treated(38.2 ± 2.5), NAG levels(mU/ear)=Untreated(23.1 ± 1.1)/Treated(27.1 ± 2.6), 6-keto-PGF1α(pg/ear)=Untreated(198 ± 22)/Treated(254 ± 26), LTB4 levels(pg/ear)=Untreated(0.30)/Treated(523 ± 128) | Ear(auditory pinna) of male Swiss Webster mice | 7646536 |
1393 | T | Capsaicin | Repeated capsaicin applications are assumed to cause desensitization of the nasal mucosa and a decreased secretory response | Immunocytochemistry, electron microscopy | The number of goblet cells was increased in the nasal region. CGRP-Iike activity was decreased in biopsies taken from the test sides of the paranasal sinuses when compared to control. | Nasal mucosa of New Zealand White rabbits | 8737771 |
1394 | RPPGFSPFR | Bradykinin | Small endogenous peptide mediators formed de novo at sites of tissue damage where it has important actions that contribute to the acute inflammatory response. | Evan's blue dye | Instillation of bradykinin increased extravasation of Evans blue dye to 93.5±7.5 ng/ml from baseline 8.54±0.93 ng/ml | Nasal mucosa of guinea pigs | 8719791 |
1397 | Botulinum neurotoxin A light chain (PFVNKQF NYKDPVNGVDIAYIKIPN AGQMQPVKAFKIHNKI WVIPERDTFTNPEEGD LNPPPEAKQVPVSYY DSTYLSTDNEKDNYLK GVTKLFERIYSTDLGR MLLTSIVRGIPFWGG STIDTELKVIDTNCIN VIQPDGSYRSEE LNLVIIGPSADIIQFE CKSFGHEVLNLTRNGY GSTQYIRFSPDFT FGFEESLEVDTNPLL | Botulinum toxin type A | Potent inhibitor of cholinergic motor nerves. | Weights of the nasal secretion were collected and compared. | Topically applied botulinum toxin reduced neurally evoked rhinorrhea by an average of 41%. | Nasal cavity of male mongrel dogs | 7700663 |
1501 | DF-Me-Phe-GLM | Senktide | NK3 tachykinin receptor agonist. Causes direct excitation of dopamine neurons; enhances dopaminergic function. Induces locomotor activity. | Radioimmunoassay | The mean maximum pupillary constriction observed with senktide (25 mg, i.v.) was 4.25+0.25 mm. | Eye of rabbit | 9351503 |